Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Renal Pelvis Cancer

H. Lee Moffitt Cancer Center and Research InstituteSmall moleculePhase 3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Renal Pelvis Cancer cohort.

Asset / SponsorPhaseRating
Vinflunine
Dr Anders Ullén
Phase 2BB
Pembrolizumab
Alliance for Clinical Trials in Oncology
Phase 3B
Icrucumab
Eli Lilly and Company
Phase 2B
Docetaxel
Eli Lilly and Company
Phase 2B
Carboplatin
Dr Anders Ullén
Phase 2B

View all 17 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →